Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing